SecBot SecBot

OCS

Oculis Holding AG
Nasdaq· Pharmaceutical Preparations· Inc. V8· CIK 0001953530 Biotech & Drug Discovery
$7.96 +0.06 (+0.76%)
Oct 26 4:00 PM ET · prev $7.90
Market cap
$498.2M
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 3
in 7 days · EPS est. −$0.40
1 year
−63.1%
from $21.56 · Oct 27
30 days
−12.1%
from $9.06
52-week range
$7.17–32.65
−76% from high · low Oct 14
Avg volume 20D
356.1K
shares / day
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 3, 2026
Strongest NEUTRAL Oculis Holding AG (OCS) filed a Form 6-K with the SEC. The filing contains routine corporate updates and…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 9 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.417 → −$0.398 over 90 days. 2 up, 2 down in 30 days.

  • TrendDOWNTREND

    22% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCDOUBLED2,042,467$28.3M
CITADEL ADVISORS LLCDOUBLED987,204$13.7M
WELLINGTON MANAGEMENT GROUP LLPTRIM540,056$7.5M
Qube Research & Technologies LtdDOUBLED262,113$3.6M
MORGAN STANLEYDOUBLED225,083$3.1M
Point72 Asset Management, L.P.DOUBLED220,403$3.1M
Alyeska Investment Group, L.P.TRIM206,332$2.9M
UBS Group AGDOUBLED182,415$2.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy7Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 23, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 18, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 14, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 5, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 3, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Jun 2, 2026Baird
MAINTAIN
MAINTAINOutperform

Earnings setup

Estimates
Nov 3
reports in 7 days
−$0.40
EPS estimate, this quarter
+4%
estimate change, 90 days
2↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.40-$0.48–-$0.30+0.0%$157.6K
Next Q-$0.43-$0.54–-$0.34+0.0%$146.0K
Current FY-$1.56-$1.70–-$1.42+0.0%$878.0K
Next FY-$1.62-$1.90–-$1.33+1.3%$4.1M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
OCS Q3 2026 Earnings Before Market Open — 2026-11-03
Recent
Oct 1, 2026
Press release
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’…
Sep 30, 2026
Press release
Oculis Announces Resignation of Lionel Carnot from Board of Directors
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company…
Sep 17, 2026
Press release
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the…
Aug 24, 2026
Press release
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address…
Aug 14, 2026
Press release
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to…

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 Other
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate brea
Sep 30, 2026 SEC
Oculis Holding AG announced the resignation of director Lionel Carnot from its Board of Directors, effective September…
6-K — Impact 2/10
Aug 10, 2026 SEC
Oculis Holding AG (OCS) filed a Form 6-K with the SEC. The filing contains routine corporate updates and standard…
6-K — Impact 5/10
Aug 10, 2026 Press
Oculis entered into an asset purchase agreement to fully acquire Accure Therapeutics' worldwide rights to Privosegtor…
Impact 5/10
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
2,042,467 shares ($28.3M)
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
987,204 shares ($13.7M)
Jun 11, 2026 Press
Oculis announced a presentation at Clinical Trials at the Summit 2026 on its lead candidate Privosegtor, a peptoid…
Impact 3/10
May 11, 2026 SEC
Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company…
PRESS-RELEASE — Impact 5/10

SecBot reports

4 filings · 9 press releases · 0 bullish · 0 bearish · 4 neutral
All OCS filing & press-release reports (13)